Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

251 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Physiological evidence for diversification of IFNα- and IFNβ-mediated response programs in different autoimmune diseases.
de Jong TD, Vosslamber S, Mantel E, de Ridder S, Wesseling JG, van der Pouw Kraan TC, Leurs C, Hegen H, Deisenhammer F, Killestein J, Lundberg IE, Vencovsky J, Nurmohamed MT, van Schaardenburg D, Bultink IE, Voskuyl AE, Pegtel DM, van der Laken CJ, Bijlsma JW, Verweij CL. de Jong TD, et al. Among authors: deisenhammer f. Arthritis Res Ther. 2016 Feb 17;18:49. doi: 10.1186/s13075-016-0946-9. Arthritis Res Ther. 2016. PMID: 26882897 Free PMC article.
Epitope specificity of neutralizing antibodies against IFN-beta.
Gneiss C, Reindl M, Berger T, Lutterotti A, Ehling R, Egg R, Deisenhammer F. Gneiss C, et al. Among authors: deisenhammer f. J Interferon Cytokine Res. 2004 May;24(5):283-90. doi: 10.1089/107999004323065066. J Interferon Cytokine Res. 2004. PMID: 15153311
Interferon-beta antibodies have a higher affinity in patients with neutralizing antibodies compared to patients with non-neutralizing antibodies.
Gneiss C, Tripp P, Ehling R, Khalil M, Lutterotti A, Egg R, Mayringer I, Künz B, Berger T, Reindl M, Deisenhammer F. Gneiss C, et al. Among authors: deisenhammer f. J Neuroimmunol. 2006 May;174(1-2):174-9. doi: 10.1016/j.jneuroim.2006.01.017. Epub 2006 Mar 23. J Neuroimmunol. 2006. PMID: 16556466 Clinical Trial.
Re: Neutralizing antibodies to interferon beta: assessment of their clinical and radiographic impact: an evidence report: report of the Therapeutics and Technology Assessment Subcommittee of the American Academy of Neurology.
Polman CH, Deisenhammer F, Giovannoni G, Killestein J, Schellekens H. Polman CH, et al. Among authors: deisenhammer f. Neurology. 2007 Oct 9;69(15):1553-4; author reply 1555. doi: 10.1212/01.wnl.0000295671.79239.f1. Neurology. 2007. PMID: 17923619 No abstract available.
Recommendations for clinical use of data on neutralising antibodies to interferon-beta therapy in multiple sclerosis.
Polman CH, Bertolotto A, Deisenhammer F, Giovannoni G, Hartung HP, Hemmer B, Killestein J, McFarland HF, Oger J, Pachner AR, Petkau J, Reder AT, Reingold SC, Schellekens H, Sørensen PS. Polman CH, et al. Among authors: deisenhammer f. Lancet Neurol. 2010 Jul;9(7):740-50. doi: 10.1016/S1474-4422(10)70103-4. Lancet Neurol. 2010. PMID: 20610349
Natalizumab treatment reduces endothelial activity in MS patients.
Millonig A, Hegen H, Di Pauli F, Ehling R, Gneiss C, Hoelzl M, Künz B, Lutterotti A, Rudzki D, Berger T, Reindl M, Deisenhammer F. Millonig A, et al. Among authors: deisenhammer f. J Neuroimmunol. 2010 Oct 8;227(1-2):190-4. doi: 10.1016/j.jneuroim.2010.07.012. Epub 2010 Aug 23. J Neuroimmunol. 2010. PMID: 20739072
Complement activating antibodies to myelin oligodendrocyte glycoprotein in neuromyelitis optica and related disorders.
Mader S, Gredler V, Schanda K, Rostasy K, Dujmovic I, Pfaller K, Lutterotti A, Jarius S, Di Pauli F, Kuenz B, Ehling R, Hegen H, Deisenhammer F, Aboul-Enein F, Storch MK, Koson P, Drulovic J, Kristoferitsch W, Berger T, Reindl M. Mader S, et al. Among authors: deisenhammer f. J Neuroinflammation. 2011 Dec 28;8:184. doi: 10.1186/1742-2094-8-184. J Neuroinflammation. 2011. PMID: 22204662 Free PMC article.
251 results